New small RNA inhibitors to target harmful oral bacteria
Official title: A New Class of Chemically Modified Small RNA Inhibitors against Fusobacterium nucleatum
Funded at University of Michigan at Ann Arbor · NIH-10875055 · Data updated 2026-11-12
This study is exploring a new way to target and eliminate a harmful bacteria called Fusobacterium nucleatum, which is linked to gum disease and colon cancer, using special RNA treatments that could help improve your oral health and lower your risk of these related health issues.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | June 30, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $167,020 |
| NIH project number | 7R03DE031329-03 |
| Project ID | NIH-10875055 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from periodontal disease or those at risk for conditions associated with Fusobacterium nucleatum.
✕Less likely to help
Patients without any oral health issues or those not affected by Fusobacterium nucleatum may not receive any benefit from this research.
What this research studies
This research investigates a novel approach to target and eliminate Fusobacterium nucleatum, a bacteria linked to various health issues, including periodontal disease and colon cancer. By utilizing chemically modified small RNA inhibitors, the study aims to selectively disrupt the activity of this bacterium within the oral microbiome. The methodology involves understanding the interactions between these inhibitors and the bacteria, potentially leading to breakthroughs in treating related diseases. Patients may benefit from improved oral health and reduced risk of associated conditions.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target harmful oral bacteria, improving overall health outcomes for patients.
How similar studies have gone: Other research has shown promise in targeting specific bacteria within the microbiome, suggesting that this approach could be effective.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Li, Jiahe — University of Michigan at Ann Arbor
- Study coordinator: Li, Jiahe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.